Title | Authors | Journal | Date | Link |
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma | Leypoldt LB et al. | J Clin Oncol. | 1 January 2024 | |
Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity | Samikshya Santosh Nirmala et al. | Front Immunology | 12 January 2024 | |
Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype | Russell Towers et al. | Cancer Immunol Immunothery | 17 January 2024 | |
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial | Platzbecker U et al. | Lancet. | 20 January 2024 | |
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL | Stelljes M et al. | J Clin Oncol. | 20 January 2024 | |
CAR T-cell therapy in multiple myeloma: mission accomplished? | Rasche L et al. | Blood. | 25 January 2024 | |
Activation of recombinases at specific DNA loci by zinc-finger domain insertions | Mukhametzyanova L et al. | Nat Biotechnol. | 31 January 2024 | |
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation | Bischof L et al. | Leukemia. | January 2024 | |
CAR T cell therapy in multiple myeloma, where are we now and where are we heading for? | Fischer L et al. | Eur J Haematol | January 2024 | |
Isolation, Ex Vivo Expansion, and Lentiviral Transduction of Alveolar Macrophages | Busch CJ-L et al. | Methods Mol Biol. | January 2024 | |
Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6 | Maximilian Walther et al. | Eur J Pharm Biopharm. | 22 February 2024 | |
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation | Jiri Eitle et al. | J Immunother Cancer. | 27 February 2024 | |
Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia | Kovtun I et al. | Leukemia. | February 2024 | |
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study | Weller JF et al. | Haematologica. | February 2024 | |
Outcomes of CMML patients undergoing allo-HCT are significantly worse compared to MDS-a study of the CMWP of the EBMT | Rovó A et al. | Am J Hematol. | February 2024 | |
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients | Mai EK et al. | Leukemia. | March 2024 | |
Microcavity well-plate for automated parallel bioelectronic analysis of 3D cell cultures | Franziska D Zitzmann et al. | Biosens Bioelectron. | 15 April 2024 | |
Spray-drying of PEI-/PPI-based nanoparticles for DNA or siRNA delivery | Sandra Noske et al. | Eur J Pharm Biopharm. | June 2024 | |
Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells | Renner A et al. | Gene Ther. | July 2024 | |
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study | Niederwieser D et al. | Haematologica. | 8 August 2024 | |
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features | Sierro-Martínez B et al. | Cell Oncol (Dordr). | 27 August 2024 | |
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma | Rade M et al. | Nat. Cancer. | 5 September 2024 | |
Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells | Staudt S et al. | bioRxiv. | 13 September 2024 | |
Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma | Kirchberg J et al. | Clin Lymphoma Myeloma Leuk. | 24 September 2024 | |
Neurological complications in oncology and their monitoring and management in clinical practice: a narrative review | Fischer S et al. | Support Care Cancer. | 25 September 2024 | |
RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma | Saleh HA et al. | Cancer Gene Ther. | September 2024 | |
Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies | Araujo AE et al. | Hum Gene Ther. | September 2024 | |
The best of both worlds: AAV-mediated gene transfer empowered by LNP delivery of Sleeping Beauty transposase for durable transgene expression in vivo | Nicolás Sandoval-Villegas et al. | Mol Ther. | 2 October 2024 | |
Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responses | von Jan J et al. | Blood. | 10 October 2024 | |
Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed/refractory multiple myeloma. | Fandrei D et al. | Blood Cancer Discov | 23 October 2024 | |
Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myeloma | Dominik Zolnowski et al. | Springer Nature Link. | 29 October 2024 | |
Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection | Navarro S et al. | Mol Ther. | 12 November 2024 | |
Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries | Récher C et al. | Am J Hematol. | 18 November 2024 | |
Cellular Therapies for Multiple Myeloma: Engineering Hope | Sarah Vera-Cruz et al. | Cancers. | 19 November 2024 | |
Single-Cell RNA Sequencing Reveals Repair Features of Human Umbilical Cord Mesenchymal Stromal Cells | Cyr-Depauw C et al. | Am J Respir Crit Care Med. | 25 November 2024 | |
Recent advances in development and delivery of non-viral nucleic acid therapeutics for brain tumor therapy. | Kögel D et al. | Pharmacol Ther. | 26 November 2024 | |
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function | Barden M et al. | J Immunother Cancer. | 2 December 2024 | |
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy | Merz M et al. | Blood Cancer. | 05 December 2024 | |
DNA binding and transposition activity of the Sleeping Beauty transposase: role of structural stability of the primary DNA-binding domain. | Ranjan VV et al. | Nucleic Acids Res. | 9 December 2024 | |
Isolation, Ex Vivo Expansion, and Lentiviral Transduction of Alveolar Macrophages | Busch CJL et al. | Methods Mol Biol. | 2024 |
